German HTA: Benefits of Roche's Perjeta are restricted
This article was originally published in Scrip
July has so far proved a mixed bag for Roche's HER2 breast cancer drug Perjeta (pertuzumab). German HTA authorities have indicated it offers additional benefit over comparators for some patients with advanced disease, but not for many others, which will likely impact the drug's reimbursement price. Meanwhile, the US FDA has granted a priority review for the drug to be used in patients with earlier stage breast cancer before surgery.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.